Brainstorm cell therapeutics abstract selected as late-breaking presentation at the 2022 mda clinical & scientific conference

New york, feb. 28, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 mda (muscular dystrophy association) clinical & scientific conference, which is taking place virtually and in-person at the gaylord opryland resort & convention center in nashville, tennessee from march 13 – 16, 2022. details on the upcoming oral presentation are provided below.
BCLI Ratings Summary
BCLI Quant Ranking